Production (Stage)
Perspective Therapeutics, Inc.
CATX
$2.39
-$0.12-4.78%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.47M | 1.45M | 1.56M | 1.46M | 1.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.47M | 1.45M | 1.56M | 1.46M | 1.53M |
| Cost of Revenue | 52.86M | 46.62M | 27.53M | 27.53M | 27.53M |
| Gross Profit | -51.16M | -44.93M | -25.98M | -26.07M | -26.01M |
| SG&A Expenses | 28.58M | 26.61M | 23.31M | 20.81M | 20.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 15.00K | 15.00K | 0.00 |
| Total Operating Expenses | 77.10M | 68.25M | 59.16M | 50.18M | 45.73M |
| Operating Income | -75.62M | -66.80M | -57.60M | -48.72M | -44.21M |
| Income Before Tax | -86.78M | -80.43M | -49.87M | -44.32M | -42.53M |
| Income Tax Expenses | -2.10M | -2.10M | 7.85M | 7.85M | 7.85M |
| Earnings from Continuing Operations | -84.68 | -78.33 | -57.71 | -52.16 | -50.38 |
| Earnings from Discontinued Operations | -488.00K | -947.00K | -6.07M | -6.86M | -8.05M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -85.17M | -79.28M | -63.79M | -59.02M | -58.42M |
| EBIT | -75.62M | -66.80M | -57.60M | -48.72M | -44.21M |
| EBITDA | -93.14M | -84.68M | -55.76M | -47.27M | -43.07M |
| EPS Basic | -1.21 | -1.21 | -1.52 | -1.67 | -1.89 |
| Normalized Basic EPS | -0.56 | -0.55 | -0.65 | -0.73 | -0.83 |
| EPS Diluted | -1.78 | -1.78 | -1.52 | -1.67 | -1.89 |
| Normalized Diluted EPS | -0.56 | -0.55 | -0.65 | -0.73 | -0.83 |
| Average Basic Shares Outstanding | 280.46M | 257.61M | 214.87M | 172.30M | 133.65M |
| Average Diluted Shares Outstanding | 280.46M | 257.61M | 214.87M | 172.30M | 133.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |